Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US/EU | 2021

Login to access report north_east
Contact sales account_box

For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
  • What are the hidden opportunities that developers could leverage?
  • How do current therapies for non-nasopharyngeal SCCHN, such as Keytruda and Opdivo, perform on key clinical attributes for this patient population?
  • What are the greatest unmet needs and most attractive opportunities in the treatment of non-nasopharyngeal SCCHN?
  • What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles for non-nasopharyngeal SCCHN?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2021

Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly

Key drugs: Erbitux, Keytruda, Opdivo

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east